How the availability of recombinant human TSH has changed the management of patients who have thyroid cancer

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Nature Clinical Practice Endocrinology &Metabolism

• Publication date

  2007-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/ncpendmet0594PMID 17710085
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patients

  2007cited by this paper
• Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients.

  2007cited by this paper
• Short-term hypothyroidism after Levothyroxine-withdrawal in patients with differentiated thyroid cancer: clinical and quality of life consequences.

  2007cited by this paper
• The role of PET in follow-up of patients treated for differentiated epithelial thyroid cancers

  2007cited by this paper
• Comparison of four strategies of follow-up in thyroid cancer patients: A cost-utility analysis

  2007cited by this paper
• A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer.

  2007cited by this paper
• Sick leave for follow-up control in thyroid cancer patients: comparison between stimulation with Thyrogen and thyroid hormone withdrawal.

  2007cited by this paper
• Monitoring thyroglobulin in a sensitive immunoassay has comparable sensitivity to recombinant human tsh-stimulated thyroglobulin in follow-up of thyroid cancer patients.

  2007cited by this paper
• Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Taskforce

  2006cited by this paper
• No Apparent Damage in the Thyroid of Transgenic Mice Expressing Antiapoptotic FLIP

  2006cited by this paper
• Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.

  2006cited by this paper
• Cost-effectiveness of using recombinant human TSH prior to radioiodine ablation for thyroid cancer, compared with treating patients in a hypothyroid state: the German perspective.

  2006cited by this paper
• Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study.

  2006cited by this paper
• A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal.

  2006cited by this paper
• European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium.

  2006cited by this paper
• Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.

  2006cited by this paper
• Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients

  2006cited by this paper
• 123I thyroid uptake and thyroid size at 24, 48, and 72 hours after the administration of recombinant human thyroid-stimulating hormone to normal volunteers.

  2006cited by this paper
• Using recombinant human thyroid‐stimulating hormone for the diagnosis of recurrent thyroid cancer

  2005cited by this paper
• rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.

  2005cited by this paper
• Thyroid Hormone Withdrawal in Patients with Differentiated Thyroid Carcinoma: A One Hundred Thirty-Patient Pilot Survey on Consequences of Hypothyroidism and a Pharmacoeconomic Comparison to Recombinant Thyrotropin Administration

  2005cited by this paper
• Compliance with follow-up and the informative value of diagnostic whole-body scan in patients with differentiated thyroid carcinoma given recombinant human TSH.

  2004cited by this paper
• Follow-up of low risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastases.

  2004cited by this paper
• Diagnostic value of serum thyroglobulin measurements in the follow‐up of differentiated thyroid carcinoma, a structured meta‐analysis

  2004cited by this paper
• Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma.

  2003cited by this paper
• Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.

  2003cited by this paper
• rhTSH stimulation before radioiodine therapy in thyroid cancer reduces the effective half-life of (131)I.

  2003cited by this paper
• Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients.

  2003cited by this paper
• Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma

  2003cited by this paper
• A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation.

  2002cited by this paper
• Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal.

  2002cited by this paper
• Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment.

  2002cited by this paper
• Sudden enlargement of local recurrent thyroid tumor after recombinant human TSH administration.

  2001cited by this paper
• Effect of various doses of recombinant human thyrotropin on the thyroid radioactive iodine uptake and serum levels of thyroid hormones and thyroglobulin in normal subjects.

  2001cited by this paper
• Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients.

  2001cited by this paper
• Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer?

  2000cited by this paper
• Hemiplegia after thyrotropin alfa in a hypothyroid patient with thyroid carcinoma metastatic to the brain.

  1999cited by this paper
• A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer.

  1999cited by this paper
• 131I Therapy for Elevated Thyroglobulin Levels

  1997cited by this paper
• Quality-of-Life Changes in Patients with Thyroid Cancer After Withdrawal of Thyroid Hormone Therapy

  1997cited by this paper
• Diagnostic accuracy of 131I scanning with recombinant human thyrotropin versus thyroid hormone withdrawal in a patient with metastatic thyroid carcinoma and hypopituitarism.

  1996cited by this paper
• Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study).

  1994cited by this paper
• Cloning of the human thyrotropin beta-subunit gene and transient expression of biologically active human thyrotropin after gene transfection.

  1988cited by this paper
• Different rates of thyrotropin suppression after total body scan in patients with thyroid cancer: effect of regular doses of thyroxine and triiodothyronine

  1983cited by this paper

• Current practice in patients with differentiated thyroid cancer

  2020cites this paper
• Treatment of refractory thyroid cancer.

  2018cites this paper
• Tumoren endokriner Organe beim alten und geriatrischen Patienten

  2018cites this paper
• [Thyroid carcinomas: the present view on diagnostics and therapy].

  2018cites this paper
• Effects of Thyroid Hormone on Urinary Concentrating Ability

  2017cites this paper
• Differentiated Thyroid Cancer—Treatment: State of the Art

  2017cites this paper
• Differenzierte Schilddrüsenkarzinome

  2015cites this paper
• Treatment of distant metastases from follicular cell-derived thyroid cancer

  2015influential citation
• Thyroid (Papillary, Follicular, Medullary, Hürthle Cell) Carcinoma Surveillance Counterpoint: Australia

  2013cites this paper
• [Radiometabolic therapy for metastatic thyroid carcinoma: overview of the literature and rational bases for the use of recombinant human TSH].

  2012cites this paper
• Follow-up of Thyroid Cancer Patients and Treatment of Distant Metastases

  2012cites this paper
• Tirotropina alfa recombinante como m étodo de estimulación en la ablación del Carcinoma Diferenciado de Tiroides

  2011cites this paper
• Current concepts and future directions in differentiated thyroid cancer.

  2010cites this paper
• To stimulate or withdraw? A cost-utility analysis of recombinant human thyrotropin versus thyroxine withdrawal for radioiodine ablation in patients with low-risk differentiated thyroid cancer in the United States.

  2010cites this paper
• Identification of a Neck Lump as a Lymph Node Metastasis from an Occult Contralateral Papillary Microcarcinoma of the Thyroid: Key Role of Thyroglobulin Assay in the Fine-Needle Aspirate

  2009cites this paper
• Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant human TSH (rhTSH): a randomized controlled study

  2009cites this paper
• Mechanisms of the pro-inflammatory action of the thyroid stimulating hormone on human abdominal subcutaneous differentiated adipocytes

  2009cites this paper
• Cancer New Drugs Group APC / DTC Briefing Recombinant TSH ( Thyrogen ® ) for ablation of thyroid remnant tissue post-thyroidectomy for thyroid cancer February 2009

  2009cites this paper
• Comment on: Recombinant human TSH in differentiated thyroid cancer: a nuclear medicine perspective

  2009cites this paper
• Radioiodine imaging and treatment in thyroid disorders.

  2008cites this paper
• Expanding Indications for Recombinant Human TSH in Thyroid Cancer

  2008cites this paper
• Seven-year follow-up of a juvenile female with papillary thyroid carcinoma with poor outcome, BRAF mutation and loss of expression of iodine-metabolizing genes.

  2008cites this paper
• Review on the Occasion of a Decade of Recombinant Human TSH: Prospects and Novel Uses

  2008cites this paper
• Overview on the use of recombinant human thyrotropin in thyroid cancer of follicular cell origin.

  2008cites this paper
• Guidelines for the management of differentiated thyroid carcinomas of vesicular origin.

  2008cites this paper
• Nontoxic Diffuse and Nodular Goiter and Thyroid Neoplasia.

  2008cites this paper
• [Guidelines for the management of differentiated thyroid cancers].

  2007cites this paper
• No Apparent Damage in the Thyroid of Transgenic Mice Expressing Antiapoptotic FLIP

  2006cites this paper